Eyal C. Attar - 16 Sep 2021 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
SVP, Chief Medical Officer
Signature
/s/ Scott M. Coiante, attorney-in-fact
Issuer symbol
APRE
Transactions as of
16 Sep 2021
Transactions value $
-$74,730
Form type
4
Filing time
20 Sep 2021, 17:29:34 UTC
Previous filing
27 Aug 2021
Next filing
01 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Sale -$74.7K -16K -16.13% $4.68 83K 16 Sep 2021 Direct F1, F2
holding APRE Common Stock 172 16 Sep 2021 By adult child F3
holding APRE Common Stock 159 16 Sep 2021 By child F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.55 to $4.85 inclusive. The reporting person undertakes to provide Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.